Literature DB >> 30446590

Neutrophil Extracellular Traps Induced by IL8 Promote Diffuse Large B-cell Lymphoma Progression via the TLR9 Signaling.

Man Nie1,2,3, Linbin Yang4,5, Xiwen Bi1,2,3, Yu Wang1,2,3, Peng Sun1,2,3, Hang Yang1,2,3, Panpan Liu1,2,3, Zhiming Li1,2,3, Yi Xia6,2,3, Wenqi Jiang6,2,3.   

Abstract

PURPOSE: More than 30% of patients with diffuse large B-cell lymphoma (DLBCL) experience treatment failure after first-line therapy. Neutrophil extracellular traps (NETs), a pathogen-trapping structure in tumor microenvironment, can promote the transition of autoimmunity to lymphomagenesis. Here, we investigate whether NETs play a novel role in DLBCL progression and its underlying mechanism.Experimental Design: NETs in DLBCL tumor samples and plasma were detected by immunofluorescence and ELISA, respectively. The correlation between NETs and clinical features were analyzed. The effects of NETs on cellular proliferation and migration and mechanisms were explored, and the mechanism of NET formation was also studied by a series of in vitro and in vivo assays.
RESULTS: Higher levels of NETs in plasma and tumor tissues were associated with dismal outcome in patients with DLBCL. Furthermore, we identified NETs increased cell proliferation and migration in vitro and tumor growth and lymph node dissemination in vivo. Mechanistically, DLBCL-derived IL8 interacted with its receptor (CXCR2) on neutrophils, resulting in the formation of NETs via Src, p38, and ERK signaling. Newly formed NETs directly upregulated the Toll-like receptor 9 (TLR9) pathways in DLBCL and subsequently activated NFκB, STAT3, and p38 pathways to promote tumor progression. More importantly, disruption of NETs, blocking IL8-CXCR2 axis or inhibiting TLR9 could retard tumor progression in preclinical models.
CONCLUSIONS: Our data reveal a tumor-NETs aggressive interaction in DLBCL and indicate that NETs is a useful prognostic biomarker and targeting this novel cross-talk represents a new therapeutic opportunity in this challenging disease. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30446590     DOI: 10.1158/1078-0432.CCR-18-1226

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  44 in total

1.  The role of neutrophil extracellular traps and TLR signaling in skeletal muscle ischemia reperfusion injury.

Authors:  Nicole J Edwards; Charles Hwang; Simone Marini; Chase A Pagani; Philip J Spreadborough; Cassie J Rowe; Pauline Yu; Annie Mei; Noelle Visser; Shuli Li; Geoffrey E Hespe; Amanda K Huber; Amy L Strong; Miriam A Shelef; Jason S Knight; Thomas A Davis; Benjamin Levi
Journal:  FASEB J       Date:  2020-10-22       Impact factor: 5.191

2.  Neutrophil Extracellular Traps Drive Mitochondrial Homeostasis in Tumors to Augment Growth.

Authors:  Hamza O Yazdani; Eva Roy; Alexander J Comerci; Dirk J van der Windt; Hongji Zhang; Hai Huang; Patricia Loughran; Sruti Shiva; David A Geller; David L Bartlett; Allan Tsung; Tai Sheng; Richard L Simmons; Samer Tohme
Journal:  Cancer Res       Date:  2019-09-13       Impact factor: 12.701

3.  Neutrophil extracellular traps induced by IL-8 aggravate atherosclerosis via activation NF-κB signaling in macrophages.

Authors:  Zhujun An; Jiawen Li; Jiangbo Yu; Xiaoli Wang; Hailai Gao; Wei Zhang; Zeren Wei; Jianchun Zhang; Yinli Zhang; Jiyi Zhao; Xiao Liang
Journal:  Cell Cycle       Date:  2019-09-08       Impact factor: 4.534

4.  Interleukin 8 Elicits Rapid Physiological Changes in Neutrophils That Are Altered by Inflammatory Conditions.

Authors:  Stefan Bernhard; Stefan Hug; Alexander Elias Paul Stratmann; Maike Erber; Laura Vidoni; Christiane Leonie Knapp; Bertram Dietrich Thomaß; Michael Fauler; Bo Nilsson; Kristina Nilsson Ekdahl; Karl Föhr; Christian Karl Braun; Lisa Wohlgemuth; Markus Huber-Lang; David Alexander Christian Messerer
Journal:  J Innate Immun       Date:  2021-04-15       Impact factor: 7.349

5.  Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures.

Authors:  Nikita Kotlov; Alexander Bagaev; Maria V Revuelta; Jude M Phillip; Maria Teresa Cacciapuoti; Zoya Antysheva; Viktor Svekolkin; Ekaterina Tikhonova; Natalia Miheecheva; Natalia Kuzkina; Grigorii Nos; Fabrizio Tabbo; Felix Frenkel; Paola Ghione; Maria Tsiper; Nava Almog; Nathan Fowler; Ari M Melnick; John P Leonard; Giorgio Inghirami; Leandro Cerchietti
Journal:  Cancer Discov       Date:  2021-02-04       Impact factor: 39.397

Review 6.  Neutrophils in Tumorigenesis: Missing Targets for Successful Next Generation Cancer Therapies?

Authors:  Fabrice Tolle; Viktor Umansky; Jochen Utikal; Stephanie Kreis; Sabrina Bréchard
Journal:  Int J Mol Sci       Date:  2021-06-23       Impact factor: 5.923

7.  Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma.

Authors:  Joseph M Tuscano; Christina Poh; Paul Kaesberg; Guilluame Luxardi; Alexander Merleev; Alina Marusina; Ann Brunson; Aaron Rosenberg; Brian Jonas; Emanual Maverakis
Journal:  Clin Cancer Res       Date:  2021-06-04       Impact factor: 13.801

Review 8.  [Research progress on neutrophil extracellular traps in tumor].

Authors:  Yiming Xu; Kejing Ying
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2020-05-25

Review 9.  Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations.

Authors:  Roberto Ferrara; Diego Signorelli; Claudia Proto; Arsela Prelaj; Marina Chiara Garassino; Giuseppe Lo Russo
Journal:  Transl Lung Cancer Res       Date:  2021-06

Review 10.  Neutrophil Extracellular Traps: A New Player in Cancer Metastasis and Therapeutic Target.

Authors:  Dakai Yang; Jing Liu
Journal:  J Exp Clin Cancer Res       Date:  2021-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.